Total raised
—
Stage
Pre-Funding
Founded
2020
Headcount
6
HQ
—
Sector
Health Tech & Life Sciences
About
SuperSpectra develops a noninvasive imaging device for the early detection and degradation followup of Alzheimer's disease by measuring CSF A and tau quantitative results. The company offers a high-accuracy quantitative measurement with real-time imaging of biomarkers of Alzheimer's disease. This noninvasive direct CSF analysis is ionizing radiation free, pain free, and risk free. Tests can be performed daily/weekly.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is SuperSpectra's primary focus?
- SuperSpectra develops a noninvasive imaging device for the early detection and degradation followup of Alzheimer's disease by measuring CSF A and tau quantitative results.
- When was SuperSpectra founded?
- SuperSpectra was founded in May 2020.
- What is the current operational status of SuperSpectra?
- SuperSpectra is currently inactive and ceased to operate in September 2024.
- How many employees did SuperSpectra have?
- SuperSpectra had between 1 and 10 employees, with an exact count of 6.
- What is SuperSpectra's current funding stage?
- SuperSpectra is in the Pre-Funding stage.
- Who are the founders of SuperSpectra?
- The founders of SuperSpectra are Yevgeny Beiderman and Zeev Zalevsky.
- What type of technology does SuperSpectra utilize?
- SuperSpectra utilizes Simulation & Imaging technology.
- What are the key benefits of SuperSpectra's device?
- SuperSpectra's device offers high-accuracy quantitative measurement with real-time imaging of Alzheimer's disease biomarkers, is noninvasive, ionizing radiation-free, pain-free, and risk-free, allowing for daily/weekly tests.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesDiagnostics Devices
Technologies
Simulation & Imaging
Target customers
Healthcare & Life SciencesHealthcareProvidersPatients
Business model
B2B2C
Tags
non-invasiveearly-detectionmedical-devicesalzheimers-diseasespectroscopy